Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 5, 2002, Pages 584-594

  Johne, Andreas ^a,b,c,d,e   Köpke, Karla ^a,b,c,d,e   Gerloff, Thomas ^a,b,c,d,e   Mai, Ingrid ^a,b,c,d,e   Rietbrock, Stephan ^a,b,c,d,e   Meisel, Christian ^a,b,c,d,e   Hoffmeyer, Sven ^a,b,c,d,e   Kerb, Reinhold ^a,b,c,d,e   Fromm, Martin F ^a,b,c,d,e   Brinkmann, Ulrich ^a,b,c,d,e   Eichelbaum, Michel ^a,b,c,d,e   Brockmöller, Jürgen ^a,b,c,d,e   Cascorbi, Ingolf ^a,b,c,d,e   Roots, Ivar ^a,b,c,d,e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Epidauros Biotechnologie AG   (Germany)

^c Institute of Clinical Pharmacology   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DIGOXIN; GLYCOPROTEIN P;

ADULT; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGOXIN BLOOD LEVEL; DRUG URINE LEVEL; EXON; GENE; GENE FREQUENCY; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; MALE; MULTIDRUG RESISTANCE GENE 1; NORMAL HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANK SUM TEST; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE;

ANIMALS; DIGOXIN; FEMALE; GENES, MDR; GENOTYPE; HAPLOTYPES; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 0036881149     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.129196     Document Type: Article

References (42)

1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999;39:361-98.
2. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 1998;251:252-61.
3. Brinkmann U, Roots I, Eichelbaum M. Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. Drug Discov Today 2001;6:835-9.
4. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987;84:7735-8.
5. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 1989;86:695-8.
6. Benet LZ, Izumi T, Zhang Y, Silverman JA, Wacher VJ. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Controlled Release 1999;62:25-31.
7. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999;104:147-53.
8. Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338-45.
9. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999;99:552-7.
10. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995;96:1698-705.
11. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101:289-94.
12. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000;97:3473-8.
13. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001;69:169-74.
14. Gerloff T, Schäfer M, Johne A, Oselin K, Meisel C, Cascorbi I, et al. MDR1 genotypes do not discriminate between absorptive pharmacokinetic parameters of a single oral dose of 1 mg digoxin in healthy white volunteers. Br J Clin Pharmacol. In press 2002.
15. Chen CJ, Clark D, Ueda K, Pastan I, Gottesman MM, Roninson IB. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem 1990;265:506-14.
16. Abernethy DR, Greenblatt DJ, Smith TW. Digoxin disposition in obesity: clinical pharmacokinetic investigation. Am Heart J 1981;102:740-4.
17. Rowland M, Tozer T. Clinical pharmacokinetics: concepts and application. 3rd ed. Baltimore: Williams & Wilkins; 1995.
18. Terwillinger J, Ott J. Handbook of human genetic linkage. Baltimore: Johns Hopkins Univ. Press; 1994.
19. Awni WM, Hussein Z, Cavanaugh JH, Granneman GR, Dube LM. Assessment of the pharmacokinetic interaction between zileuton and digoxin in humans. Clin Pharmacokinet 1995;29:92-7.
20. Mooradian AD. Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. Clin Pharmacokinet 1988;15:165-79.
21. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and Native Americans. Clin Pharmacol Ther 2001;70:189-99.
22. Lacarelle B, Rahmani R, de Sousa G, Durand A, Placidi M, Cano JP. Metabolism of digoxin, digoxigenin digitoxosides and digoxigenin in human hepatocytes and liver microsomes. Fundam Clin Pharmacol 1991;5:567-82.
23. Haji SA, Movahed A. Update on digoxin therapy in congestive heart failure. Am Fam Physician 2000;62:409-16.
24. Chiou WL, Chung SM, Wu TC, Ma C. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int J Clin Pharmacol Ther 2001;39:93-101.
25. Kerb R, Aynacioglu AS, Brockmöller J, Schlagenhaufer R, Bauer S, Szekeres T, et al. The predictive value of drug uptake and metabolism for phenytoin plasma levels: a combined analysis of MDR1, cytochrome P450 2C9 and 2C19 polymorphisms. Pharmacogenomics J 2001;1:204-10.
26. Hitzl M, Drescher S, van der Kuip H, Schaffeler E, Fischer J, Schwab M, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001;11:293-8.
27. Becquemont L, Verstuyft C, Kerb R, Brinkmann U, Lebot M, Jaillon P, et al. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 2001;70:311-6.
28. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001;18:1400-4.
29. Shon J, Chun H, Kim K, Kim E, Yoon Y, Jang I, et al. The PK and PD of fexofenadine in relation to MDR1 genetic polymorphism in Korean healthy subjects. Clin Pharmacol Ther 2002;71:P71.
30. Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002;53:526-34.
31. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001;47:1048-52.
32. Pauli-Magnus C, Feiner J, Brett C, Lin ET, Kroetz DL. No effect of MDR1 C3435T polymorphism on disposition and CNS effects of loperamide [abstract]. Clin Pharmacol Ther 2002;71:P72.
33. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 2002;71:297-303.
34. Calado RT, Falcao RP, Garcia AB, Gabellini SM, Zago MA, Franco RF. Influence of functional MDR1 gene polymorphisms on P-glycoprotein activity in CD34+ hematopoietic stem cells. Haematologica 2002;87:564-8.
35. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002;71:11-20.
36. König J, Cui Y, Nies AT, Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 2000;275:23161-8.
37. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, et al. Organic anion transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001;120:525-33.
38. Suzuki A, Tirona RG, Leake B, Echizen H, Takahashi H, Miyake F, et al. Polymorphisms in the digoxin uptake transporter OATP-8, among Japanese, African-, and European-American subjects [abstract]. Clin Pharmacol Ther 2002;71:P104.
39. Pauli-Magnus C, DeYoung J, Herskowitz I, Giacomini KM, Clark AG, Kroetz DL. Ethnic variation in MDR1 haplotype structure [abstract]. Clin Pharmacol Ther 2002;71:P35.
40. Saito S, Iida A, Sekine A, Miura Y, Ogawa C, Kawauchi S, et al. Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the Japanese population. J Hum Genet 2002;47:38-50.
41. Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K, et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A 2000;97:10483-8.
42. Hoehe MR, Köpke K, Wendel B, Rohde K, Flachmeier C, Kidd KK, et al. Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. Hum Mol Genet 2000;9:2895-908.